Gluject-M 1000 Tablet ER is a combination oral antidiabetic medication containing Dapagliflozin 10 mg and Metformin 1000 mg extended-release. It is indicated for the management of type 2 diabetes mellitus in adults, particularly in patients inadequately controlled on diet and exercise alone or those already receiving monotherapy. Dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, reduces renal glucose reabsorption, promoting glucosuria and thereby lowering plasma glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to enhanced glycemic control. The extended-release formulation allows for once-daily dosing, improving patient adherence and minimizing gastrointestinal side effects commonly associated with immediate-release metformin. Gluject-M 1000 Tablet ER should be used as part of a comprehensive diabetes management plan including diet, exercise, and regular blood glucose monitoring. It is contraindicated in patients with severe renal impairment, metabolic acidosis, or hypersensitivity to its components. Caution is advised in patients with risk factors for ketoacidosis or volume depletion. Regular monitoring of renal function and glycemic parameters is recommended during therapy. This combination offers a complementary mechanism of action to achieve effective glycemic control in type 2 diabetes mellitus.